AZN.UK

12,550

+0.5%↑

GSK

1,635

-1.57%↓

HLN.UK

329

-0.6%↓

STJ

1,297.5

+1.21%↑

HIK

1,854

+2.43%↑

AZN.UK

12,550

+0.5%↑

GSK

1,635

-1.57%↓

HLN.UK

329

-0.6%↓

STJ

1,297.5

+1.21%↑

HIK

1,854

+2.43%↑

AZN.UK

12,550

+0.5%↑

GSK

1,635

-1.57%↓

HLN.UK

329

-0.6%↓

STJ

1,297.5

+1.21%↑

HIK

1,854

+2.43%↑

AZN.UK

12,550

+0.5%↑

GSK

1,635

-1.57%↓

HLN.UK

329

-0.6%↓

STJ

1,297.5

+1.21%↑

HIK

1,854

+2.43%↑

AZN.UK

12,550

+0.5%↑

GSK

1,635

-1.57%↓

HLN.UK

329

-0.6%↓

STJ

1,297.5

+1.21%↑

HIK

1,854

+2.43%↑

Inicio・Lista de Acciones・PureTech Health Plc

PureTech Health Plc

Cerrado

140 0.86

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

134.4

Máximo

141.2

Métricas clave
By Trading Economics
Ingresos	70M
Ventas	4M
P/B Media del Sector	9.969 35.739
BPA	-0.19
Margen de beneficios	1,727.216
Empleados	56
EBITDA	102M

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	313M
Apertura anterior	139.14
Cierre anterior	140

PureTech Health Plc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

1 oct 2025, 18:59 UTC

Principales Movimientos del Mercado

Intel Shares Rise on Reported Talks to Add AMD as Customer

1 oct 2025, 23:47 UTC

Charlas de Mercado

Nikkei May Rise After Gains on Wall Street -- Market Talk

1 oct 2025, 23:45 UTC

Charlas de Mercado

Gold Edges Lower on Likely Technical Correction -- Market Talk

1 oct 2025, 23:12 UTC

Adquisiciones, fusiones, absorciones

Avalanche Treasury CEO is Bart Smith

1 oct 2025, 23:11 UTC

Adquisiciones, fusiones, absorciones

Avalanche Treasury Investors Include Dragonfly, VanEck, Galaxy Digital and Others

1 oct 2025, 23:07 UTC

Adquisiciones, fusiones, absorciones

Avalanche Treasury Plans to Own More Than $1B Worth of AVAX After Becoming a Public Company

1 oct 2025, 23:06 UTC

Adquisiciones, fusiones, absorciones

Avalanche Treasury Co. Has an Exclusive Relationship With Avalanche Foundation

1 oct 2025, 23:04 UTC

Adquisiciones, fusiones, absorciones

Avalanche Treasury: Transaction Includes About $460M in Treasury Assets

1 oct 2025, 22:41 UTC

Charlas de Mercado

Flight Centre Set for Calm Year After Turbulent FY 2025 -- Market Talk

1 oct 2025, 22:41 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

1 oct 2025, 22:34 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

1 oct 2025, 22:34 UTC

Charlas de Mercado

AGL Energy Is Less Risky Than the Market Thinks -- Market Talk

1 oct 2025, 22:25 UTC

Ganancias

Webco Industries 4Q EPS $9.18 >WEBC

1 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

1 oct 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

1 oct 2025, 20:33 UTC

Adquisiciones, fusiones, absorciones

Roche Begins Tender Offer for 89bio Pursuant to Previously Announced Merger Agreement

1 oct 2025, 20:30 UTC

Adquisiciones, fusiones, absorciones

Sherwin-Williams Completes $1.15B Purchase of BASF's Brazilian Architectural Paints Business

1 oct 2025, 20:20 UTC

Adquisiciones, fusiones, absorciones

These Stocks Moved the Most Today: Nike, Netflix, Fermi, Moderna, AES, Lithium Americas, Sunrun, Corteva, and More -- Barrons.com

1 oct 2025, 20:19 UTC

Adquisiciones, fusiones, absorciones

GPP Deal Includes Enel's Interests in Oklahoma, Minnesota and North Dakota Facilities

1 oct 2025, 20:16 UTC

Adquisiciones, fusiones, absorciones

GPP Buys All of Enel's Cash-Equity Interests in Five Operating Wind Facilities and Divests a Portion of Its Interests in Two Wind Facilities

1 oct 2025, 20:16 UTC

Adquisiciones, fusiones, absorciones

Harbert Management's Gulf Pacific Power Expands Operating Wind Portfolio in Transaction With Enel Green Power North America

1 oct 2025, 20:13 UTC

Adquisiciones, fusiones, absorciones

This Lithium Stock Is Soaring Again. How Government Money Is Giving It a Boost. -- Barrons.com

1 oct 2025, 20:04 UTC

Charlas de Mercado

Crude Oil Extends Losing Streak -- Market Talk

1 oct 2025, 19:49 UTC

Charlas de Mercado

Natural Gas Surges on Short-Covering Rally -- Market Talk

1 oct 2025, 19:30 UTC

Charlas de Mercado

Precious Metals Jump After Government Closes -- Market Talk

1 oct 2025, 18:15 UTC

Charlas de Mercado

Canada Tamps Down Talk of Dairy Trade Concessions -- Market Talk

1 oct 2025, 18:09 UTC

Charlas de Mercado

Ganancias

Nike and Adidas Duopoly is Back -- Market Talk

1 oct 2025, 18:08 UTC

Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Nike, Netflix, Fermi, Moderna, AES, Lithium Americas, Sunrun, Corteva, and More -- Barrons.com

1 oct 2025, 17:45 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

1 oct 2025, 17:45 UTC

Charlas de Mercado

Canadian House Prices Could Be in For Steady Stretch -- Market Talk

Comparación entre iguales

Cambio de precio

PureTech Health Plc previsión

Consenso

By TipRanks

0 ratings

Comprar

Mantener

Vender

De acuerdo con 0 analistas que ofrecen calificaciones bursátiles a para PureTech Health Plc Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de PureTech Health Plc

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.